公开(公告)号：EP1317559A2

公开(公告)日：2003-06-11

申请号：EP01932704.8

申请日：2001-04-27

申请人： ST. JUDE CHILDREN'S RESEARCH HOSPITAL

发明人： HOFFMANN, Erich

IPC分类号： C12N15/85 ,  C12N15/44 ,  C07K14/11 ,  A61K39/145 ,  C12N7/04

CPC分类号： C07K14/005 ,  A61K2039/5252 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2720/00063 ,  C12N2760/16122 ,  C12N2760/16151 ,  C12N2760/16163 ,  C12N2760/16222 ,  C12N2760/16263 ,  C12N2760/18663 ,  C12N2770/24263 ,  C12N2800/107 ,  C12N2800/40 ,  C12N2830/205 ,  C12N2830/34 ,  C12N2830/36 ,  C12N2830/85

摘要： The present invention is based on the development of a dual promoter system (preferably a RNA pol I -pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.

公开(公告)号：EP1317559B1

公开(公告)日：2009-01-07

申请号：EP01932704.8

申请日：2001-04-27

申请人： ST. JUDE CHILDREN'S RESEARCH HOSPITAL

发明人： HOFFMANN, Erich

IPC分类号： C12N15/85 ,  C12N15/44 ,  C07K14/11 ,  A61K39/145 ,  C12N7/04

CPC分类号： C07K14/005 ,  A61K2039/5252 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2720/00063 ,  C12N2760/16122 ,  C12N2760/16151 ,  C12N2760/16163 ,  C12N2760/16222 ,  C12N2760/16263 ,  C12N2760/18663 ,  C12N2770/24263 ,  C12N2800/107 ,  C12N2800/40 ,  C12N2830/205 ,  C12N2830/34 ,  C12N2830/36 ,  C12N2830/85

摘要： The present invention is based on the development of a dual promoter system (preferably a RNA pol I -pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.

公开(公告)号：EP0720851A3

公开(公告)日：1999-12-22

申请号：EP95117773.2

申请日：1995-11-11

申请人： BEHRINGWERKE Aktiengesellschaft

发明人： Bernhardt, Dieter, Dr.

IPC分类号： A61K31/47 ,  A61K31/535 ,  A61K31/54 ,  A61K31/14

CPC分类号： C12N7/00 ,  A01N43/42 ,  A61L2/0088 ,  A61L2/18 ,  C12N7/06 ,  C12N2760/18663 ,  A01N33/12 ,  A01N2300/00

摘要： Die Erfindung betrifft die Verwendung von Acridin oder Acridinderivaten, bevorzugt in Kombination mit Benzalkoniumchlorid, zur Inaktivierung von umhüllten oder nicht umhüllten Viren. Das erfindungsgemäße Verfahren wird bevorzugt in Gegenwart von Proteinen durchgeführt, deren biologische Aktivität dabei weitgehend erhalten bleibt.

摘要翻译： 灭活病毒，包括使用吖啶或DERIV的吖，是新的。

公开(公告)号：EP2085468A1

公开(公告)日：2009-08-05

申请号：EP08019287.5

申请日：2001-04-27

申请人： ST. JUDE CHILDREN'S RESEARCH HOSPITAL

发明人： Hoffmann, Erich

IPC分类号： C12N7/04 ,  C12N15/85 ,  C12N15/44 ,  C07K14/11 ,  A61K39/145

CPC分类号： C07K14/005 ,  A61K2039/5252 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2720/00063 ,  C12N2760/16122 ,  C12N2760/16151 ,  C12N2760/16163 ,  C12N2760/16222 ,  C12N2760/16263 ,  C12N2760/18663 ,  C12N2770/24263 ,  C12N2800/107 ,  C12N2800/40 ,  C12N2830/205 ,  C12N2830/34 ,  C12N2830/36 ,  C12N2830/85

摘要： The present invention is based on the development of a dual promoter system (preferably a RNA pol I -pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.

摘要翻译： 本发明基于用于病毒RNA的有效细胞内合成的双重启动子系统（优选RNA pol I -pol II系统）的开发。 所得到的基于最小质粒的系统可用于合成任何RNA病毒，优选具有负单链RNA基因组的病毒。 当将系统的质粒引入合适的宿主细胞时，产生该系统的病毒产物。 该系统的一个应用是生产用作疫苗中抗原的减毒重配流感病毒。 通过共转染质粒产生的重配病毒可以包含编码来自目前感染群体的流感病毒的表面糖蛋白血凝素和神经氨酸酶的基因以及来自减毒流感病毒的内部基因。 本发明的有利特征是其多功能性; 该系统可以快速且容易地适应于合成任何RNA病毒的减毒版本。 本发明产生的减毒或灭活的RNA病毒可以通过包括鼻内或肌肉内的几种途径中的任何途径施用于需要接种疫苗的患者。

公开(公告)号：EP1322329A1

公开(公告)日：2003-07-02

申请号：EP01986267.1

申请日：2001-10-01

申请人： GlaxoSmithKline Biologicals S.A.

发明人： COLAU, Brigitte D.A.,GlaxoSmithKline Biologicals ,  DESCHAMPS, Marguerite,GlaxoSmithKline Biologicals

IPC分类号： A61K39/155 ,  C12N7/06 ,  A61K39/295 ,  A61P31/12

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/155 ,  A61K2039/543 ,  A61K2039/55505 ,  A61K2039/55544 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/70 ,  C12N2760/18534 ,  C12N2760/18563 ,  C12N2760/18634 ,  C12N2760/18663 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/396

摘要： The invention relates to vaccine formulation comprising a split enveloped virus preparation wherein the virus RSV or PIV, methods of preparing such formulation, and use of such formulations in prevention or treatment of disease.

公开(公告)号：EP0720851A2

公开(公告)日：1996-07-10

申请号：EP95117773.2

申请日：1995-11-11

申请人： BEHRINGWERKE Aktiengesellschaft

发明人： Bernhardt, Dieter, Dr.

IPC分类号： A61K31/47 ,  A61K31/535 ,  A61K31/54 ,  A61K31/14

CPC分类号： C12N7/00 ,  A01N43/42 ,  A61L2/0088 ,  A61L2/18 ,  C12N7/06 ,  C12N2760/18663 ,  A01N33/12 ,  A01N2300/00

摘要： Die Erfindung betrifft die Verwendung von Acridin oder Acridinderivaten, bevorzugt in Kombination mit Benzalkoniumchlorid, zur Inaktivierung von umhüllten oder nicht umhüllten Viren. Das erfindungsgemäße Verfahren wird bevorzugt in Gegenwart von Proteinen durchgeführt, deren biologische Aktivität dabei weitgehend erhalten bleibt.

摘要翻译： 灭活病毒，包括使用吖啶或DERIV的吖，是新的。